Implementation of the analysis
The GynTect® test is based on the detection of DNA methylation in human gene regions. During the process of DNA methylation, methyl groups are attached to DNA. These are always cytosines located next to guanines (‘CpG dinucleotides’).
|Kit||PCR device||Kit Size||Samples to be analysed simultaneously|
|GT012-10||ABI 7500 Real-Time PCR-System (Life Technologies by Thermo Fisher Scientific)||10 samples||10|
|GT012-06||ABI 7500 Real-Time PCR-System (Life Technologies by Thermo Fisher Scientific)||6 samples||1-6|
|GT003-10||cobas z 480 Analyzer (Roche)||10 samples||10|
|GT003-06||cobas z 480 Analyzer (Roche)||6 samples||1-6|
GynTect® detects malignant transformations
An existing infection with HPV may lead to genetic instability of the infected cells and eventually cervical cancer. In the course of carcinogenesis, changes (methylation) occur in the DNA.
If the Pap test is abnormal or the HPV test is positive in cervical cancer screening, the affected patient is suddenly in an exceptional situation, as both tests indicate a potential cancer. In many cases, however, no malignant disease is present and the positive test result was a false alarm. For definitive medical clarification, further examinations are necessary, such as a colposcopy, and if necessary, a colposcopy-guided biopsy. In case of abnormalities, the allegedly affected tissue is often removed prematurely.